Radiology Groups Push UnitedHealthcare and Cigna to Update Payment Policies for Key Service

Why It Matters

Reclassifying PNS as a covered service could broaden treatment options for chronic‑pain patients and lower overall healthcare costs by reducing invasive surgeries.

Key Takeaways

• Insurers label PNS experimental despite two decades of data.
• Ten societies demand policy revision for peripheral nerve stimulation.
• Studies show over 70% pain reduction across multiple conditions.
• PNS risk profile lower than many surgical pain interventions.
• Access to PNS could reduce reliance on invasive procedures.

Pulse Analysis

Peripheral nerve stimulation has moved from niche therapy to a mainstream option for chronic pain management over the past twenty years. By delivering low‑frequency electrical signals to targeted nerves, PNS interrupts pain pathways without the tissue disruption associated with spinal cord stimulators or joint surgeries. Peer‑reviewed trials published in journals such as Pain Medicine and Neuromodulation consistently demonstrate average pain reductions exceeding 70 percent, along with improvements in mobility and quality of life. Moreover, the procedure’s minimally invasive nature translates into shorter hospital stays, lower infection rates, and a reduced need for postoperative opioid prescriptions.

Despite this growing evidence base, UnitedHealthcare and Cigna continue to categorize PNS as experimental, limiting reimbursement for both outpatient and inpatient settings. The classification forces physicians to navigate prior‑authorization hurdles, often resulting in delayed care or patients bearing out‑of‑pocket costs. For radiology groups, the policy creates a financial disincentive to invest in the specialized equipment and training required for PNS implantation. Insurers argue that long‑term cost‑effectiveness data are insufficient, yet health‑economics models suggest that avoiding costly surgeries and chronic opioid therapy could yield net savings within two years.

If the insurers revise their policies, the ripple effect could reshape pain‑care delivery across the United States. Expanded coverage would likely accelerate adoption of PNS in ambulatory surgery centers, driving competition among device manufacturers and spurring innovation in lead design and programming algorithms. Payers would also benefit from a more predictable utilization pattern, enabling value‑based contracts that tie reimbursement to patient‑reported outcomes. Ultimately, aligning coverage with contemporary clinical guidelines positions the healthcare system to address the chronic pain epidemic more efficiently while preserving provider autonomy and patient choice.